Cochrane Review Finds Limited Efficacy in Alzheimer's Amyloid Drugs
A Cochrane Collaboration review has concluded that amyloid beta-targeting drugs for Alzheimer's disease show limited clinical efficacy. The analysis, which included data from 17 clinical trials involving 20,342 participants, found that these drugs have minimal impact on cognitive decline and dementia severity, while increasing the risk of brain bleeding and swelling. The review specifically examined Eisai/Biogen's Leqembi and Eli Lilly's Kisunla, among others. Despite some statistically significant results in early trials, the review emphasizes the lack of meaningful clinical benefits for patients. The findings have sparked debate among researchers, with some advocating for exploring alternative treatment mechanisms. 
